Opus Genetics, Inc. (IRD) Stock Score, Valuation & Financial Research
Opus Genetics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 27/100.
Quick answer for IRD
Opus Genetics, Inc. currently has a Wall Street Score of 27/100. The stored market price is $6.07. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Opus Genetics, Inc. does
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed
IRD financial snapshot
- Wall Street Score:
- 27/100
- Current price:
- $6.07
- Market capitalization:
- $501.2M
- Revenue:
- $9.9M
- Net income:
- $-107.6M
- Free cash flow:
- $-35.3M
- Cash:
- $88.8M
- Total debt:
- $34.9M
- EPS:
- -1.30
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -0.3%.
- Free cash flow is $-35.3M, showing cash burn in the current stored period.
- The balance sheet shows $88.8M of cash versus $34.9M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.1 points: IRD increased 0.1 points because overall fundamentals improved.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research IRD
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.